Copyright © Inderes 2011 - present. All rights reserved.

NextCell Pharma

1.30 SEK

+1.25 %

Less than 1K followers

NXTCL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+1.25 %
-8.45 %
+77.84 %
+90.34 %
+21.04 %
-61.08 %
-74.56 %
-88.99 %
-41.21 %

NextCell Pharma operates in the healthcare sector. The company develops stem cell products that are mainly used in the treatment of autoimmune diabetes and kidney transplantation. A large part of the work consists of stem cell research where the company develops drug candidates that will facilitate and increase acceptance in organ transplantation. In addition, the company owns a stem cell bank. The company was founded in 2014 and has its headquarters in Huddinge.

Read more
Market cap
144.81M SEK
Turnover
368.69K SEK
Revenue
10.94M
EBIT %
-328.01 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/5
2026

General meeting '26

28/5
2026

Interim report Q1'26

27/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Results are out. The report is still messy and incomplete. CEO comments are conspicuous by their absence, etc. This started in the previous quarterly report after the CFO left. Apparently, the new CFO has not fixed the issue. The report covers an exceptional 16-month financial year...
2/26/2026, 9:11 AM
5
New press release and the stock is showing new momentum, up 12% today. For the sharp-eyed, however, this isn’t new information, because even though Nextcell hasn’t communicated this directly to investors, yours truly spotted this 29 days ago in this discussion.
2/18/2026, 2:11 PM
5
Interesting questions that I have also been pondering. Is the internal funding from Cellaviva and Qvance etc. sufficient? I remember the CEO stating in some presentation that Qvance would reach profitability by the end of the current year. Cell and tissue sales haven’t grown very...
2/14/2026, 8:48 AM
by Timo Rousi
4
The company is truly an extreme example of poor liquidity for a listed company. Last Friday at the open: 10:03 share 1.68 (+7%) 10:05 share 1.51 (-4%) Today the range was even wider. At the open, it rose +9.5%, and a couple of minutes later, it dipped to -5.5%. Hardly any trades ...
2/23/2026, 12:23 PM
2
Now the valuation has doubled, and rising revenue can, with some luck, justify it as well. Haven’t investors sufficiently accounted for the potential of these subsidiaries’ operations? I don’t believe they’ve been given much weight, as not a single euro has been seen yet. The company...
2/17/2026, 2:03 PM
2
I remember the CEO stating in some presentation that Qvance would reach profitability by the end of the current year. Are you referring to this interview with the CEO of Qvance? linkedin.com 🎬 Live from Nordic Life Science Days! What amazing energy at our booth... 🎬 Live from Nordic...
2/16/2026, 12:17 PM
2
How do fellow investors see NextCell’s chances of avoiding another share issue before the results for the youth study? And what will the market reaction be if NextCell succeeds during 2026? -NextCell had 38.7 MSEK at the end of August 2025. -It consumes about 8–9 MSEK per quarter...
2/12/2026, 12:44 PM
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.